{"id":451,"date":"2020-08-20T11:57:51","date_gmt":"2020-08-20T11:57:51","guid":{"rendered":"https:\/\/nclinnovations.org\/covid19monitor\/?p=451"},"modified":"2020-08-20T11:57:51","modified_gmt":"2020-08-20T11:57:51","slug":"11-aug-2020-lopinavir-r-and-hydroxychoroquine-several-adverse-events-and-no-effect-on-clinical-course","status":"publish","type":"post","link":"https:\/\/nclinnovations.org\/covid19monitor\/11-aug-2020-lopinavir-r-and-hydroxychoroquine-several-adverse-events-and-no-effect-on-clinical-course\/","title":{"rendered":"(11 Aug 2020) Lopinavir\/R and Hydroxychoroquine- several adverse events and no effect on clinical course"},"content":{"rendered":"<div class=\"boldgrid-section\">\n<div class=\"container\">\n<div class=\"row\">\n<div class=\"col-md-12 col-xs-12 col-sm-12\">\n<p>Early administration of lopinavir\/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study<\/p>\n<p><a href=\"https:\/\/doi.org\/10.1002\/jmv.26407\">https:\/\/doi.org\/10.1002\/jmv.26407<\/a><\/p>\n<p class=\"\">This was a retrospective intent-to-treat analysis of the hospitalized patients who started LPV\/r+HCQ between 21 February and 20 March 2020. The association between the timing of treatment and the probability of 30-day mortality was assessed using uni- and multivariable logistic models. The study involved 172 patients: 43 (25%) in the ET and 129 (75%) in the DT group. The rate of clinical improvement increased over time to 73.3% on day 30, without any significant difference between the two groups (Gray&#8217;s test P=0.213). After adjusting for potentially relevant clinical variables, there was no significant association between the timing of the start of treatment and the probability of 30-day mortality (adjusted odds ratio [aOR] ET vs DT=1.45, 95% confidence interval 0.50-4.19). Eight percent of the patients discontinued the treatment because of severe gastrointestinal disorders attributable to LPV\/r. The timing of the start of LPV\/r+HCQ treatment does not seem to affect the clinical course of hospitalised patients with COVID-19. Together with the severe adverse events attributable to LPV\/r, this raises concerns about the benefit of using this combination to treat COVID-19.<\/p>\n<\/div>\n<\/div>\n<\/div>\n<\/div>\n","protected":false},"excerpt":{"rendered":"<p>Early administration of lopinavir\/ritonavir plus hydroxychloroquine does not alter the clinical course of SARS-CoV-2 infection: a retrospective cohort study https:\/\/doi.org\/10.1002\/jmv.26407 This was a retrospective intent-to-treat analysis of the hospitalized patients who started LPV\/r+HCQ between 21 February and 20 March 2020.&hellip; <span class=\"read-more-span\"><a href=\"https:\/\/nclinnovations.org\/covid19monitor\/11-aug-2020-lopinavir-r-and-hydroxychoroquine-several-adverse-events-and-no-effect-on-clinical-course\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;(11 Aug 2020) Lopinavir\/R and Hydroxychoroquine- several adverse events and no effect on clinical course&#8221;<\/span> <span class=\"genericon genericon-next\"><\/span><\/a><\/span><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"bgseo_title":"","bgseo_description":"","bgseo_robots_index":"index","bgseo_robots_follow":"follow"},"categories":[4,9,12],"tags":[10,41],"_links":{"self":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/451"}],"collection":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/comments?post=451"}],"version-history":[{"count":1,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/451\/revisions"}],"predecessor-version":[{"id":452,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/posts\/451\/revisions\/452"}],"wp:attachment":[{"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/media?parent=451"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/categories?post=451"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/nclinnovations.org\/covid19monitor\/wp-json\/wp\/v2\/tags?post=451"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}